RxDoctor Payments Data

Ansy John

Psychiatric/Mental Health · Las Vegas, NVNPI 1265660047

Payments from drug & device makers

$2,021in general payments, 2019–2025

Across 100 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$573
  • Otsuka America Pharmaceutical, Inc.$540
  • Alkermes, Inc.$370
  • E.r. Squibb & Sons, L.L.C.$209
  • AbbVie$141
  • Neuronetics, Inc.$36
  • plus $153 from 6 others

What the payments were for

  • Food & beverage$2,021100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,021 in reported general payments places this provider in the 70th percentile of 362 psychiatric/mental health providers in Nevada.

See all psychiatric/mental health providers in Nevada

Medicare billing

Part B allowed, 2024
$58,533
Medicare patients
115
Services billed
677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole20$34,453
VraylarCariprazine Hcl14$22,246
Lamotrigine1,243$14,997
TrintellixVortioxetine Hydrobromide11$14,832
Quetiapine Fumarate909$12,427
Aripiprazole382$9,334
Trazodone Hcl476$5,308
Bupropion XlBupropion Hcl248$5,193
Duloxetine Hcl287$5,054
Oxcarbazepine101$4,419
Hydroxyzine Hcl268$4,339
Ziprasidone Hcl63$4,084
Lurasidone Hcl53$3,526
Buspirone Hcl317$3,439
Sertraline Hcl539$3,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$540$34,45320 claims
AbbVieVraylar$141$22,24614 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$15$14,83211 claims
Almatica Pharma LLCSertraline Hcl$21$3,415539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 362 psychiatric/mental health providers in Nevada.

Other psychiatric/mental health in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →